We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARD
2676
DELISTED
Ardagh Group S.A. Class A Common Shares
ARD
| $250K | ﹤0.01% |
12,749
+2
| +0% | +$37 |
|
2677
Lexicon Pharmaceuticals
LXRX
$1.03B
| $249K | ﹤0.01% |
60,107
+1,359
| +2% | +$5.23K |
|
2678
Northeast Bank
NBN
$1.13B
| $248K | ﹤0.01% |
11,286
+250
| +2% | +$5.52K |
|
2679
Ohio Valley Banc Corp
OVBC
$201M
| $248K | ﹤0.01% |
6,254
-23
| -0.4% | -$863 |
|
2680
Phreesia
PHR
$698M
| $248K | ﹤0.01% |
9,295
+707
| +8% | +$19.5K |
|
2681
Arq
ARQ
$86.3M
| $248K | ﹤0.01% |
23,624
+80
| +0.3% | +$956 |
|
|
SRGA
2682
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $248K | ﹤0.01% |
3,012
+4
| +0.1% | +$280 |
|
|
DLA
2683
DELISTED
Delta Apparel Inc.
DLA
| $247K | ﹤0.01% |
+7,929
| New | +$212K |
|
2684
SoundThinking
SSTI
$102M
| $246K | ﹤0.01% |
9,662
+61
| +0.6% | +$1.36K |
|
2685
FVCBankcorp
FVCB
$337M
| $244K | ﹤0.01% |
17,486
+445
| +3% | +$6.16K |
|
2686
Natural Gas Services Group
NGS
$468M
| $244K | ﹤0.01% |
19,888
-54
| -0.3% | -$636 |
|
2687
Red River Bancshares
RRBI
$670M
| $244K | ﹤0.01% |
+4,350
| New | +$207K |
|
2688
Peoples Bancorp of North Carolina
PEBK
$231M
| $243K | ﹤0.01% |
7,392
+48
| +0.7% | +$1.46K |
|
|
PBIP
2689
DELISTED
Prudential Bancorp, Inc.
PBIP
| $243K | ﹤0.01% |
13,128
-59
| -0.4% | -$1.04K |
|
|
TREC
2690
DELISTED
Trecora Resources
TREC
| $241K | ﹤0.01% |
33,690
-56
| -0.2% | -$458 |
|
2691
Wave Life Sciences
WVE
$1.18B
| $237K | ﹤0.01% |
29,547
+387
| +1% | +$9.49K |
|
2692
MetroCity Bankshares
MCBS
$1.02B
| $236K | ﹤0.01% |
+13,490
| New | +$202K |
|
2693
Quad
QUAD
$559M
| $236K | ﹤0.01% |
50,442
-249
| -0.5% | -$1.56K |
|
|
PTVCB
2694
DELISTED
Protective Insurance Corporation Class B Common Stock
PTVCB
| $235K | ﹤0.01% |
14,607
-255
| -2% | -$4.15K |
|
|
CBIO
2695
Crescent Biopharma
CBIO
$552M
| $234K | ﹤0.01% |
442
+3
| +0.7% | +$1.62K |
|
2696
Talphera
TLPH
$69M
| $234K | ﹤0.01% |
5,548
+64
| +1% | +$2.61K |
|
2697
Boston Omaha
BOC
$437M
| $233K | ﹤0.01% |
11,079
+184
| +2% | +$3.86K |
|
|
SNCR
2698
DELISTED
Synchronoss Technologies
SNCR
| $233K | ﹤0.01% |
5,461
+98
| +2% | +$4.35K |
|
2699
Chemung Financial Corp
CHMG
$393M
| $231K | ﹤0.01% |
5,447
-6
| -0.1% | -$262 |
|
2700
CEL-SCI Corp
CVM
$21.8M
| $231K | ﹤0.01% |
841
+13
| +2% | +$3.07K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.